Study record
IMerge Phase 3: imetelstat (telomerase INHIBITOR) in lower-risk MDS (Platzbecker et al., 2024)
Human clinical-outcome RCT — disease population (randomized Phase 3)
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase expression is low in many differentiated normal tissues, while some normal proliferating cells can express it. Cancer can also use telomere maintenance; the included human records do not resolve long-term cancer risk from pharmacological activation. Tellingly, the FDA-approved telomerase inhibitor — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 2 — Human clinical-outcome trial — disease population
Record verify: source publication identified; see evidence and limitations
| Design | Randomized, double-blind, placebo-controlled Phase 3 trial (transfusion-independence outcome) |
| N | 178 |
| Registry | NCT02598661 |
| DOI | 10.1016/S0140-6736(23)01724-5 |
| Citation status | Original publication identity matched by title, author and DOI; relevant full-text sections, results and limitations examined 2026-10-14. The trial identifier is reported in the original source. |
Five-qualifier claim
| Species / population | 178 patients in randomized IMerge Phase 3 (118 imetelstat, 60 placebo), with transfusion-dependent IPSS low/intermediate-1 MDS and inadequate/lost ESA response or ESA ineligibility. Registry NCT02598661 covers more than this randomized phase and must not supply its cohort denominator. |
| Exposure, route, schedule | The FDA Drug Trials Snapshot reports RYTELO 7.1 mg/kg by intravenous infusion every 28 days in the randomized trial. |
| Comparator / duration | Randomized, double-blind, placebo-controlled, multinational Phase 3. |
| Endpoint / numeric result | FDA reported ≥8-week red-cell transfusion independence in 39.8% versus 15.0% and ≥24-week independence in 28.0% versus 3.3% (imetelstat vs placebo). FDA approval on 6 June 2024 is for adults requiring ≥4 red-cell units/8 weeks with insufficient/lost ESA response or ineligibility, not all lower-risk MDS. |
| What it did NOT establish | Cancer/hematology treatment via telomerase INHIBITION in a disease population — the OPPOSITE mechanistic direction from anti-aging 'activation'. Not an aging trial and not a lifespan outcome. |
Interventions
Primary reference
https://doi.org/10.1016/S0140-6736(23)01724-5
Each identifier above was confirmed against the primary record; the citation status names the source and the date. An identifier that could not be confirmed is left empty and named as such in the record, never filled in from a secondary source.